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NLRP1 has long remained an elusive member of the NOD-like-receptor family of innate immune sensors. In
this issue of Immunity, Masters et al. (2012) describe its role in immune responses to stress and infection.The human body is under constant attack
by various pathogenic members of the
microbial world. In order to cope with
these threats, an elaborate system of
innate receptors evolved to guard the
sanctity of tissues, lumen, fluids, and
cells. The NOD-like-receptor (NLR) family
of innate receptors is specialized in
recognizing intracellular threats, given
that they continuously scan the cellular
cytoplasm for signals of potential hazards
(Strowig et al., 2012). The founding
members of the NLR family, NOD1 and
NOD2, were among the first intracellular
innate immune receptors described and
are genuine pattern-recognition receptors
that recognize and respond to bacterial
peptidoglycan fragments by inducing
NF-kB-mediated immune responses. In
addition to NOD1 and NOD2, several
more NLRs have been discovered over
the last decade. One of the breakthroughs
that led to their identification was the
finding that a group of related autoinflam-
matory disorders, now collectively called
cryopyrin-associated periodic syndrome
(CAPS), is caused by point mutations in
the gene encoding NLRP3 (also called
cryopyrin) (Hoffman et al., 2001). In
healthy cells, NLRP3 remains in an inac-
tive state. After receptor activation, a
multiprotein complex consisting of the
adaptor protein ASC and caspase-1 is
rapidly formed, enabling the proteolytic
activation of caspase-1. Active caspase-1
subsequently processes the leaderless
proinflammatory cytokines interleukin-1b
(IL-1b) and interleukin-18 (IL-18), leading
to their secretion from the cell. Active
caspase-1 also initiates a specific type
of inflammatory cell death called pyropto-
sis (Strowig et al., 2012). Key in regulating
this process is the requirement for
a priming signal, for instance, LPS (signal
1); only then can NLRP3 activation (signal
2) lead to successful cytokine secretion950 Immunity 37, December 14, 2012 ª2012and pyroptosis. In many CAPS-affected
individuals, NLRP3 is believed to be in
an ‘‘always-on’’ or hypersensitive state,
which leads to uncontrolled and/or
continuous inflammation as a result of
the loss of requirement for signal 2. In
addition to NLRP3, several other NLRs
have now been shown to be able to form
large protein complexes, or ‘‘inflamma-
somes,’’ that enable the activation of cas-
pase-1. These include NLRC4 (sensing
bacterial flagellin and a component of the
type III secretion system), AIM2 (sensing
DNA), NLRP6 (involved in sensing intes-
tinal barrier disruption), and NLRP1 (Stro-
wig et al., 2012; Elinav et al., 2011).
Although NLRP1 was the first NLR that
was shown to form an inflammasome
(Martinon et al., 2002), its exact function
has remained relatively unclear. In hu-
mans, NLRP1 polymorphisms have been
associated with a variety of autoimmune
diseases, including Addison’s disease
and vitiligo (Jin et al., 2007). Human
NLRP1 has been proposed to recognize
muramyl dipeptide, the bacterial peptido-
glycan fragment that also activates
NOD2 (Faustin et al., 2007). In mice,
NLRP1 consists of three homologs,
termed NLRP1a, NLRP1b, and NLRP1c
(predicted to be a pseudogene). NLRP1b
exhibits great variability among different
inbred mice strains; the form that is
believed to be the ‘‘functional’’ receptor
is activated by anthrax lethal toxin (Boy-
den and Dietrich, 2006). For NLRP1a, no
ligand or function has been found as of
yet.
In the search for new candidate genes
that induce neutrophilia, Masters et al.
(2012) performed N-ethyl-N-nitrosourea
random mutagenesis in mice and thus
produced a mutant presenting with a
systemic inflammatory phenotype char-
acterized by massive multiorgan neutro-
phil influx. The authors identified theElsevier Inc.responsible mutation as a glutamine-to-
proline substitution in the linker region
between the nucleotide-binding domain
and leucine-rich-repeat domain of
NLRP1a (NLRP1aQ593P). Because similar
mutations in NLRP3 from CAPS-affected
individuals have been described to result
in an ‘‘always-on’’ receptor status lead-
ing to uncontrolled inflammation, the
response of NLRP1aQ593P bone-marrow-
derived macrophages to LPS was investi-
gated. Whereas wild-type macrophages
required an additional inflammasome
stimulus like ATP or alum (signal 2), cells
carrying the NLRP1aQ593P mutation re-
sponded by producing IL-1b without the
need for the crucial second signal; this
latter finding is indicative of continuous
receptor and inflammasome activation.
To examine the mechanism of
NLRP1aQ593P-induced pathology in more
detail, Masters et al. (2012) crossed
NLRP1aQ593P mice with mice lacking key
molecules in inflammasome activation
and signaling. Using this approach, the
authors identified caspase-1 and inter-
leukin-1R, but not interleukin-1a, as
critical for the induction of systemic
inflammation, leaving IL-1b as the major
cytokine-driving pathology. Interestingly,
the adaptor protein ASC was found to
be dispensable for this phenotype. ASC
is the crucial protein bridge between pyrin
domains of NLRs and CARD domains
of caspase-1; the lack of a pyrin domain
in NLRP1a (which ‘‘directly’’ contains
a CARD domain) might explain the ASC
independency. This places NLRP1a apart
from both NLRP3 (which contains a pyrin
domain and requires ASC) and NLRC4
(which contains only a CARD domain but
requires ASC for efficient IL-1b secretion)
(Broz et al., 2010). Caspase-11, which has
been linked to NLRP1 in earlier studies,
was also dispensable for NLRP1aQ593P-
induced systemic inflammation.
Figure 1. Schematic View of NLRP1-Mediated Immune Responses
Constitutively active NLRP1 results in caspase-1-dependent IL-1b secretion that drives systemic inflam-
mation and in IL-18 that negatively regulates systemic inflammation through an unknown mechanism.
NLRP1 and caspase-1-dependent pyroptosis in bone-marrow cells increase the susceptibility to the
chemotherapy agent 5-fluorouracil and LCMV infection, which themselves induce massive bone-marrow
cell stress and death. IL-1b counteracts the pyroptosis-mediated bone-marrow cell death and suscepti-
bility to 5-flourouracil and LCMV infection through emergency granulopoiesis. Deletion of NLRP1
increases the resistance to 5-fluorouracil and LCMV as a result of the absence of NLRP1-dependent py-
roptosis in bone-marrow cells.
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produced during NLRP1aQ593P inflamma-
some activation, had a more complex
role in the inflammation phenotype.
Through bone-marrow-transplant experi-
ments, Masters et al. (2012) show that
large quantities of IL-18were produced by
the hematopoietic cells of NLRP1aQ593P
mice. However, deletion of the cytokine
in the NLRP1aQ593P background led to
increased mortality, most likely as a result
ofmore severemyocarditis. This suggests
that IL-18 might play a protective role
during systemic inflammation. In an
attempt to unravel the mechanism
behind this finding, the authors crossed
NLRP1aQ593P mice with mice deficient in
interferon-g (IFN-g), a major cytokine
downstream of IL-18. However, deletion
of IFN-g did not phenocopy the IL-18
mutation. Although the precise role of
IL-18was not further elucidated, its induc-
tion was shown to be dependent on the
presence of the microbiota given that
germ-free NLRP1aQ593P mice no longer
succumbed more rapidly in the absence
of IL-18.
Although the IL-1b-signaling path-
way was clearly the driving force
behind the inflammatory phenotype inNLRP1aQ593P mice, two additional path-
ways contributed in a more subtle
way that is worth mentioning. First,
Ifng/ mice carrying the NLRP1aQ593P
mutation developed encephalitis that
was not seen in NLRP1aQ593P mice, sug-
gesting a tissue-specific suppressive
role for IFN-g in NLRP1aQ593P-induced
inflammation in the brain. Second,
NLRP1aQ593P on a T-cell-deficient back-
ground resulted in an increase in der-
matitis, which apparently is prevented
by T cells during systemic IL-1b-driven
inflammation.
Unrestricted IL-1b signaling drives
powerful systemic inflammation. Using
this knowledge, Masters et al. (2012)
were able to unmask in NLRP1aQ593P
mice an additional phenotype involving
NLRP1aQ593P-driven pyroptosis by exam-
ining NLRP1aQ593P, Il1r1/ double
mutant mice. Characterization of these
mice revealed an overall reduced number
of hematopoietic stem cells and progen-
itor cells of both myeloid and lymphoid
lineages under homeostatic condi-
tions. Because these deficiencies were
not seen in the NLRP1aQ593P mice, the
authors concluded that granulopoiesis
induced by IL-1bmasks the loss of hema-Immunity 37, Dtopoietic cells that died by uncontrolled
pyroptosis. To extend this pheno-
type to more physiological situations,
NLRP1aQ593P, Il1r1/micewereexposed
to 5-fluorouracil chemotherapy or lym-
phocytic-choriomeningitis-virus (LCMV)
infection, which can both induce hemato-
poietic cell death. In both cases,
NLRP1aQ593P, Il1r1/ mice were more
susceptible than control Il1r1/ mice.
Finally, and in accordance with the model
of NLRP1a-driven bone-marrow cell
pyroptosis, Masters et al. (2012) showed
that mice triple deficient in NLPR1a,
NLRP1b, and NLRP1c exhibited in-
creased numbers of hematopoietic stem
and progenitor cells and increased resis-
tance to 5-flourouracil treatment and
LCMV infection.
The activating mutation in NLRP1a
identified by Masters et al. (2012) shows
a dramatic inflammatory phenotype
(Figure 1). However, when NLRP3 muta-
tions found in CAPS-affected individuals
were introduced into mice, an even more
striking pathology was observed: most
mice died within two weeks (Brydges
et al., 2009). This could be a reflection of
either the expression profile of NLRP1a
versus NLRP3 or the differences in
‘‘strength’’ between the individual muta-
tions. An alternative explanation could
be that the different signaling domains in
NLRP1a and NLRP3 (CARD versus pyrin)
might regulate the level of caspase-1
activation. Intriguingly, human NLRP1
contains both a CARD and a pyrin
domain. It would be of great interest to
determine the relative contribution of the
individual domains to inflammation in
both healthy and pathological conditions.
Masters et al. (2012) convincingly show
that hyperactive NLRP1a causes mas-
sive systemic inflammation and that the
absence of NLRP1 in mice leads to a
hematopoietic compartment that is better
able to deal with local stress and infection.
But is it only bad news with NLRP1? Are
these negative effects the price that the
immune system pays in order to fight
off still-unidentified threats? Or does
NLRP1-mediated cell death also have
beneficial effects? One intriguing hypoth-
esis might be that NLRP1 orchestrates
the removal of damaged cells that are
no longer able to effectively function
or that might cause problems in the
future—e.g. mutagenized cells that might
become transformed— but at the cost ofecember 14, 2012 ª2012 Elsevier Inc. 951
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Previewsdecreased ability to survive acute hema-
topoietic stress. Perhaps the evolutionary
pressure on murine NLRP1, shown both
by its apparent divergence into three
homologs and the existence of multiple
forms of NLRP1b, is an example of the
intricate balance between the beneficial
and harmful functions of NLRP1. The final
answermight comewith the elucidation of
the exact ligands or cellular conditions
that activate NLRP1 in mice and humans.
This, together with the work by Masters
et al. (2012), should begin to clarify the
various roles of NLRP1 in host defense
and homeostasis.952 Immunity 37, December 14, 2012 ª2012REFERENCES
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Interleukin-22 (IL-22) enhancesmucosal barrier function and is important in antimicrobial host defense. In this
issue of Immunity, Basu et al. (2012) reveal that Th22 cells are the critical adaptive source of IL-22 during
late-phase infection by Citrobacter rodentium.Interleukin-22 (IL-22) belongs to the IL-10
cytokine family and is expressed by
innate and adaptive lymphocytes
(Ouyang et al., 2011). IL-22 binds to a
heterodimeric receptor consisting of IL-
22R1 and IL-10R2. IL-22R1, the ligand
binding subunit, is expressed by nonhe-
matopoietic cells such as the epithelial
cells of the gastrointestinal tract and
skin. Therefore, IL-22 functions as a
signaling mediator that can connect
lymphocytes and epithelial cells. IL-22-
IL-22R signaling in epithelial cells results
in expression of genes involved in
antimicrobial host defense including
S100 proteins, defensins, Lipocalin 2,
and RegIII-family proteins. IL-22 also
induces inflammatory molecules such
as chemokines and cytokines including
IL-6. In addition, IL-22 has an important
function in tissue repair via induction of
epithelial cell proliferation and survival.
By inducing such genes and by enhanc-ing epithelial barrier function, IL-22
plays an important role in promoting
resistance to extracellular pathogens,
particularly to Gram-negative pathogens.
Indeed, IL-22 signaling is essential for
protective immunity to extracellular
Klebsiella pneumoniae in the lung and
Citrobacter rodentium in the intestine
(Aujla et al., 2008; Sonnenberg et al.,
2011; Zheng et al., 2008). IL-22 signaling
is also required to prevent systemic
dissemination of the Alcaligenes bacteria
species, which are normally commensal
and constitutively reside within the
Peyer’s patches (Sonnenberg et al.,
2012). In addition, IL-22 prevents tissue
destruction in several mouse models.
In a ConcanavalinA-induced hepatitis
model, IL-22 protects from liver injury
by enhancing the growth and survival
of hepatocytes. In the intestine, IL-22
prevents tissue destruction in dextran
sodium sulfate-mediated colitis and ina mouse model of graft versus host
disease. In contrast, dysregulated IL-
22-IL-22R signaling can promote patho-
logical inflammatory responses in the
skin and intestine in mouse models, and
the concentration of IL-22 is increased
in a variety of human diseases including
psoriasis, rheumatoid arthritis, and
inflammatory bowel diseases. Further-
more, excessive and aberrant IL-22
signaling results in colon cancer develop-
ment, as exemplified by mice lacking
IL-22-binding protein (IL-22BP), a soluble
high-affinity decoy receptor for IL-22
(Huber et al., 2012).
Innate lymphoid cells (ILCs) are one of
the major sources of IL-22 (Sonnenberg
and Artis, 2012). IL-22-producing ILCs
include CD4+ lymphoid-tissue inducer-
like cells and NKp46+ natural killer-like
cells and are now referred to as group
3 ILCs (ILC3s) (Sonnenberg and Artis,
2012). IL-22+ ILC3s mainly reside in
